TCM product approved for sale in Singapore


Lianhua Qingwen, a recommended medicine for treating patients with mild COVID-19 symptoms, has been approved as a Chinese proprietary medicine by the Health Sciences Authority in Singapore.
The designation means the product can be sold in the country as a medicine, the drug's manufacturer said on Wednesday.
Made by Shijiazhuang Yiling Pharmaceutical Co, in Shijiazhuang, Hebei province, the medicine meets Singapore's standards for registration as a Chinese patent medicine, it said.
The capsule, a traditional Chinese medicine used in the treatment of influenza, has been approved for sale as a medicine, food supplement or natural health product in a dozen countries and regions, including Brazil, Romania, Thailand and Ecuador. It can also be sold in the Hong Kong and Macao special administrative regions.
- Lai condemned for citing 'threats' to call for hiking 'defense' spending
- Govt to soon allow private cars to enter Hong Kong from Guangdong
- Zhangjiajie National Forest Park emerges after rain like a fairyland
- Shanghai summer kicks off with 'Easy Go'
- Miao ethnic carnival in Hunan draws thousands
- Hebei roasted lamb contest blends history, tourism